COR — Cencora, Inc. stock price, charts and financials

QT59Cencora, Inc.

Cencora, Inc. (NYSE: COR) is a Healthcare company in the Medical - Distribution industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
309.41
-9.09-2.85%
CORQT59Cencora, Inc.·NYSE
309.41-2.85%
News
Down 2.9% — Corient Private Wealth LP Purchases 19,068 Shares of Cencora, Inc. $COR (defenseworld.net).
Medium confidence
TA
Loading chart...
Signal & projected range
Insider open-market saleHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
Snapshot
IndexS&P 500P/E22.99EPS (ttm)13.46Insider Own14.03%Shs Outstand194.56MPerf Week-3.60%
Market Cap60.20BForward P/E15.62EPS next Y19.81Insider Trans-0.02%Shs Float182.66MPerf Month-2.13%
Enterprise Value69.11BPEG1.49EPS next Q4.57Inst Own-Short Float2.48%Perf Quarter11.66%
Income2.63BP/S0.18EPS this Y32.80%Inst Trans-Short Ratio3.11Perf Half Y-4.85%
Sales332.77BP/B18.59EPS next Y10.83%ROA3.13%Short Interest4.53MPerf YTD-8.39%
Book/sh16.65P/C21.39EPS next 5Y15.43%ROE106.43%52W High377.56 -18.05%Perf Year6.69%
Cash/sh14.47P/FCF15.41EPS past 3/5Y-0.33% -ROIC12.75%52W Low244.83 26.38%Perf 3Y73.36%
Dividend Est.2.40 (0.78%)EV/EBITDA13.46Sales past 3/5Y10.43% 11.09%Gross Margin3.71%Volatility2.29% 2.00%Perf 5Y150.33%
Dividend TTM2.40 (0.78%)EV/Sales0.21EPS Y/Y TTM78.75%Oper. Margin1.30%ATR (14)7.45Perf 10Y252.60%
Dividend Ex-DateAug 14, 2026Quick Ratio0.58Sales Y/Y TTM13.20%Profit Margin0.79%RSI (14)39.79Recom2.30
Dividend Gr. 3/5Y6.46% 5.77%Current Ratio0.93EPS Q/Q7.47%SMA20-4.54%Beta0.57Target Price358.14
Payout17.83%Debt/Eq6.15Sales Q/Q5.07%SMA50-2.24%Rel Volume0.75Prev Close318.50
Employees49,000LT Debt/Eq5.94EarningsNov 04SMA200-3.34%Avg Volume1.44MPrice309.41
IPO DateApr 04, 1995Option/ShortYes / YesEPS/Sales Surpr.-1.42% -3.37%Net Debt/EBITDA1.74Volume1,077,810Change-2.85%
Analyst Ratings
DateActionAnalystRatingTarget
Aug-19-26ReiteratedRBC CapitalSector Perform$330
Aug-07-26ReiteratedMorgan StanleyOverweight$342$346
Aug-06-26ReiteratedRobert W. Baird$340$370
Aug-06-26ReiteratedUBSBuy$412$430
Aug-06-26ReiteratedEvercore ISI GroupOutperform$360$350
Jun-10-26ReiteratedBarclaysOverweight$425$350
May-11-26ReiteratedWells FargoOverweight$429$331
May-08-26ReiteratedMorgan StanleyOverweight$400$342
May-07-26ReiteratedUBSBuy$415$412
Apr-08-26ReiteratedEvercore ISI GroupOutperform$420$360
Latest News· Times ET
Sep-16-26
Sep-15-26
Sep-14-26
Sep-11-26
Sep-10-26
Sep-08-26
Sep-07-26
Sep-04-26
Sep-03-26
Sep-02-26
Aug-31-26
Company

Cencora, Inc. functions as a global leader in the sourcing and distribution of pharmaceutical products, with operations spanning both the United States and international markets. Within its U.S. Healthcare Solutions segment, the company supplies a broad spectrum of pharmaceutical items, including generic and injectable medications, over-the-counter health products, and home healthcare equipment. Its extensive client network includes acute care hospitals, health systems, a variety of retail and mail-order pharmacies (independent, chain, long-term care), medical clinics, and other healthcare providers. This division also manages the distribution of crucial specialized pharmaceutical products like plasma, blood derivatives, and vaccines. Beyond product supply, Cencora offers comprehensive support services, such as pharmacy management, staffing solutions, and strategic consulting. It develops and implements supply management software, provides packaging services for both institutional and retail healthcare settings, and assists with clinical trial support, post-market approval processes, and commercialization strategies. For biotechnology and pharmaceutical manufacturers, the company delivers data analytics, outcomes research, and other specialized services. Furthermore, Cencora serves the animal health market, providing pharmaceuticals, vaccines, parasiticides, diagnostics, and micro feed ingredients for both companion and production animals. It also offers sales force support to manufacturers and specialized services to medical professionals, particularly oncologists, as well as to hospitals and dialysis clinics. The International Healthcare Solutions division concentrates on global pharmaceutical wholesale activities, associated services, and worldwide commercialization support. It ensures the efficient distribution of medicines, various healthcare goods, and related services to an international customer base comprising pharmacies, doctors, health centers, and hospitals. This segment also delivers specialized transportation and logistics solutions specifically designed for the biopharmaceutical sector. Founded in 1871, the company was formerly known as AmerisourceBergen Corporation before adopting the name Cencora, Inc. in August 2023. Its corporate headquarters are situated in Conshohocken, Pennsylvania.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
FY 2025
9/30/2025
FY 2024
9/30/2024
FY 2023
9/30/2023
FY 2022
9/30/2022
FY 2021
9/30/2021
FY 2020
9/30/2020
FY 2019
9/30/2019
FY 2018
9/30/2018
Total Revenue332,772321,333293,959
Cost of Goods Sold Incl. D&A320,426311,191285,257
Gross Profit12,34510,1428,701
Selling, General and Administrative Excl. Other7,6546,4945,661
Research and Development
000
Other Operating Expense
35500
Operating Income4,3363,6483,040
Interest Expense497420249
Unusual Expense
Non-Operating Income (Expense)-231-970-787
Net Income Before Taxes3,6072,2582,004
Income Taxes968691485
Consolidated Net Income2,6251,5541,509
Net Income From Continuing Operations2,6401,5681,519
Net Income2,6251,5541,509
EPS (Recurring)13.528.027.60
EPS (Basic, Before Extraordinaries)13.528.027.60
EPS (Diluted)13.467.967.53
EBITDA5,1333,7363,364
Other After Tax Adjustments
Stock Option Compensation Expense
Price To Earnings Ratio22.9939.2629.89
Price To Sales Ratio0.180.190.15
Gross Margin3.713.162.96
Operating Margin1.301.141.03
Net Margin0.790.480.51
Shares Outstanding193194199
Market Capitalization59,71660,63144,791
Operating Lease Expense
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$393.05$353.40$313.75$274.09$234.44 Close Price0.00M2.64M5.28M7.92M10.57MUSD Trades VolumeSepOctNovDec2026FebMarAprMayJunJulAugSep
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
GREENBERG LON RDirectorSep 16 '26Sale321.301,280411,26417,128Sep 17
Krikorian LazarusSVP & Chief Accounting OfficerSep 01 '26Sale325.97985321,08016,169Sep 02
Campbell Elizabeth SExecutive Vice PresidentAug 24 '26Sale324.1211,3003,662,66319,455Aug 25
Tyler Lauren MDirectorJun 22 '26Buy270.23550148,6274,359Jun 24
DURCAN DERMOT MARKDirectorJun 18 '26Buy274.194,0001,096,76031,767Jun 22
DURCAN DERMOT MARKDirectorMay 28 '26Buy266.264,0001,065,04027,767May 28
Battaglia SilvanaExecutive Vice PresidentMar 11 '26Option Exercise0.008,415027,239Mar 13
Campbell Elizabeth SExecutive Vice PresidentMar 11 '26Option Exercise0.0012,623036,548Mar 13
Cleary James FChief Financial OfficerMar 11 '26Option Exercise0.0012,6230165,766Mar 13
Mauch Robert P.President & CEOFeb 20 '26Sale358.943,7621,350,33265,393Feb 24
Mauch Robert P.President & CEOFeb 20 '26Option Exercise86.093,762323,87169,155Feb 24
Mauch Robert P.President & CEOFeb 18 '26Sale359.461,333479,16065,393Feb 20
Mauch Robert P.President & CEOJan 20 '26Sale354.735,0961,807,70466,726Jan 22
Mauch Robert P.President & CEOJan 20 '26Option Exercise86.093,763323,95771,822Jan 22
Battaglia SilvanaExecutive Vice PresidentDec 19 '25Sale345.001,677578,56518,796Dec 22
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.